EStudio de Biodisponibilidad de dos preparados comerciales de teofilina

Greenberger PA. Prospetive evaluation of elevated serum theophylline concentrations to determine if high concentrations are predictable. Am J Med 1991; 95: 67-9.

Kuma N, Ashutosh N. Use of serum theophylline level as a guide to optimun therapy in patients with chronic obstructive lung disease. J Clin Pharmacol 1990; 30: 324-29.

Gibaldi M. Biopharmaceutis and clinical pharmacokinetics. 3rd ed. Philadelphia; Lea & Febiger. 1984. Pp. 77-8.

American Medical Association. Drugs evaluations. 6th ed. Philadelphia; WB Saunders. 1986. Pp. 406-11.

Monzón D. Introducción al diseño de experimentos. 2ª ed. Maracay; Universidad Central de Venezuela. 1986. Pp. 50-8.

Bowman WC, Rand MJ. Texbook of pharmacology. 2nd ed. London; Blackwell Scientific Publications. 1980. Pp. 40-5.

Avendaño C. Introducción a la química farmacéutica. New York; Interamericana McGraw-Hill. 1993. Pp. 278-88.

Dunagan W, Claiborne R. Manual de terapéutica médica. 7ª ed. Departament of Medicine, Washington University. 1991. Pp. 249-50.

Trnavska Z. Theophylline protein binding. Arzeimttelforschung 1990; 40: 166-67.

Capps N. General practice theophylline audit in the Exeter Health District. J Clin Pharm Ther 1990; 15: 101-07.

Soto J, Sacristán JA. Concentraciones plasmáticas de teofilina en los pacientes con enfermedad pulmonar obstructiva crónica. Med Clin 1992; 98: 60-5.

Chandler MHH. Home monitoring of theophylline levels: a novel therapeutic approah. Pharmacotheraphy 1990; 10: 294-300.

Gibaldi M, Perrier D. Pharmacokinetics. Vol 1. Marcel Dekker, New York, 1975.